An Unanticipated Diagnosis and a Resilient Response: A Lung Cancer Patient Shares Her Story timesunion.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from timesunion.com Daily Mail and Mail on Sunday newspapers.
ABBVie today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® plus VENCLEXTA ® VENCLYXTO ® versus chlorambucil plus obinutuzumab for first-line treatment in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who had active disease requiring treatment per the International Workshop on CLL criteria. The study met its primary …
ABBVie (NYSE: ABBV) today announced new data from the Phase 3 GLOW study comparing the efficacy and safety of the combination of IMBRUVICA ® (ibrutinib) plus VENCLEXTA ® VENCLYXTO ® (venetoclax) (I+V) versus chlorambucil plus obinutuzumab (C+O) for first-line treatment in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who had active disease requiring treatment per the International Workshop on CLL (iwCLL) criteria. The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review c
no
ocular findings and an overall safety profile in line with what we saw in the monotherapy setting. It’s
notable
to see this kind of activity in patients with ER+ metastatic breast cancer, where there is a clear need for new therapeutic options.”
In this preliminary analysis from the open-label AMEERA-1 study, amcenestrant was evaluated in dose escalation cohorts (Part C) at 200mg (n=9) and 400mg (n=6) daily and in a dose expansion cohort (Part D; n=30) at 200mg daily, all in combination with a standard dose of palbociclib. Eligible patients included post-menopausal women with ER+/HER2- MBC who were pre-treated with endocrine therapy in the advanced setting for at least six months or had resistance to adjuvant endocrine therapy.
Sanofi: Early amcenestrant data featured at ASCO support its potential to become a new endocrine backbone therapy for ER+/HER2- breast cancer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.